Item 7.01 Regulation FD Disclosures

The Company will present data at the 2020 NASH-TAG Conference in Park City, Utah on January 9-11th. The Company's materials to be used in the various presentations are attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4, 99.5 and 99.6.

Item 9.01 Financial Statements and Exhibits.






(d)    Exhibits

The following exhibits are filed with this report:

Exhibit No. Description



  99.1        Abstract "LPCN 1144 (Oral Testosterone Undecanoate) Resolves
            Non-Alcoholic Fatty Liver Disease"

  99.2        Abstract "An ongoing clinical phase 2 study (LiFT trial) of oral
            testosterone undecanoate (LPCN 1144) in subjects with nonalcoholic
            steatohepatitis (NASH)"

  99.3        Abstract "A High-Fat-Diet Induced Non-Alcoholic Steatohepatitis
            (NASH) Rabbit Model to Assess Potential Preventive Treatment with an
            Oral LPCN 1144"

  99.4        Poster "LPCN 1144 (Oral Testosterone Undecanoate) Resolves
            Non-Alcoholic Fatty Liver Disease"

  99.5        Poster "A High-Fat-Diet Induced Non-Alcoholic Steatohepatitis
            (NASH) Rabbit Model to Assess Potential Preventive Treatment with an
            Oral LPCN 1144"

  99.6        Display Poster "LPCN 1144 and LPCN 1148 Overview"

© Edgar Online, source Glimpses